Drug Type Bispecific antibody |
Synonyms ABL 103, ABL-103 |
Target |
Mechanism 4-1BB inhibitors(Tumor necrosis factor receptor superfamily member 9 inhibitors), B7-H4 inhibitors(V-set domain-containing T-cell activation inhibitor 1 inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePhase 1 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Advanced Malignant Solid Neoplasm | Phase 1 | KR | 07 Nov 2023 | |
Metastatic Solid Tumor | Phase 1 | KR | 07 Nov 2023 | |
Triple Negative Breast Cancer | Preclinical | KR | 25 Jul 2023 | |
Solid tumor | Preclinical | US | - |